Physician

Evan Z Lang, MD

According to 2025 Medicare claims, Evan Lang, MD (NPI: 1639163033) practices medical oncology in the Cincinnati, OH-KY-IN market, with the plurality of this provider's patient population coming from Butler, OH. This provider's primary affiliated billing organization is ONCOLOGY HEMATOLOGY CARE INC (NPI: 1790778041; TIN: 311106418) and primary practice location at 45014-5376. Lang is affiliated with the Mercy Health Select, LLC (ACO ID: A1215), participating under the MSSP model.

Lang's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 609 traditional Medicare patients, billed 150,324 HCPCS/CPT codes, and received $3,170,546 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 2,754 prescription claims across 421 beneficiaries totaling $6,391,561 in drug costs, led by Pomalyst (Pomalidomide). 2022 DME data shows 44 claims. Open Payments data shows 36 records totaling $6,353. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has changed little. Concurrently, Part D prescription costs have moved from a lower plateau to a higher plateau, from $3,034,336 to $6,391,561. In contrast, DME billing represents a smaller volume and declined steadily, from $4,669 to $3,318.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	786	222,527	$2,376,025
2016	844	277,123	$3,239,734
2017	874	225,676	$3,254,602
2018	833	267,239	$4,102,980
2019	837	252,932	$3,643,126
2020	709	228,675	$3,734,811
2021	769	205,658	$3,334,352
2022	714	201,876	$2,967,664
2023	659	171,875	$2,948,424
2024	609	150,324	$3,170,546

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	319	2,701	$3,034,336
2016	301	2,432	$3,259,688
2017	367	2,537	$4,081,361
2018	342	2,881	$4,915,033
2019	365	3,048	$5,986,331
2020	412	3,042	$5,996,535
2021	383	2,784	$6,672,701
2022	369	2,626	$6,102,664
2023	414	2,949	$6,901,812
2024	421	2,754	$6,391,561

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	66	$4,835
2016	52	239	$42,349
2017	N/R	159	$18,832
2018	26	316	$80,239
2019	N/R	153	$16,720
2020	N/R	139	$9,341
2021	N/R	131	$7,138
2022	N/R	44	$3,288
2023	N/R	N/R	N/R
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	138	202	$88
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	336	570	$60
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	268	372	$12
80053	Blood test, comprehensive group of blood chemicals	155	374	$10
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	320	908	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Pomalyst	Pomalidomide	49	1,372	$1,084,748
Lenalidomide	Lenalidomide	62	1,729	$657,081
Ninlaro	Ixazomib Citrate	38	1,064	$501,680
Verzenio	Abemaciclib	33	924	$383,275
Ibrance	Palbociclib	22	616	$346,040

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	36	$6,353	AstraZeneca Pharmaceuticals LP
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Evan Z. Lang, MD?

Tedicare shows public-source Medicare data for Evan Z. Lang, MD (NPI 1639163033), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Evan Z. Lang, MD have ACO affiliation data?

Evan Z. Lang, MD is shown with ACO affiliation data for Mercy Health Select, LLC (MSSP, ACO ID A1215).

What billing organization is linked to Evan Z. Lang, MD?

Evan Z. Lang, MD is linked to ONCOLOGY HEMATOLOGY CARE INC (billing NPI 1790778041) in the available physician profile data.

Does Evan Z. Lang, MD have Open Payments data?

Evan Z. Lang, MD has 36 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.